Startups channel feed

Tar­get­ing tox­ic pro­tein ag­gre­ga­tion, Ger­man biotech banks €12M to de­vel­op drug for rare neu­rode­gen­er­a­tive dis­or­der

6 years ago
Financing

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

6 years ago
Financing
Cell/Gene Tx

Chris Var­ma un­veils MP­M's lat­est start­up — eye­ing 'un­drug­gable' can­cer tar­gets and pow­ered by ma­chine learn­ing, $67M

6 years ago
Financing

Ox­ford, Evotec ramp up LAB10x with AI ex­perts at Sen­syne — fo­cused on biotech spin­outs

6 years ago
AI

David de Graaf now has his $28.5M launch round in place, build­ing a coen­zyme A plat­form in his lat­est start­up

6 years ago
Financing

Philadel­phia cham­pi­ons life sci­ences 'co-work­ing,' re­viv­ing for­mer GSK cam­pus in $500M makeover

6 years ago

Adding mar­quee in­vestors, Black­Thorn bags $76M to back an AI-dri­ven strat­e­gy for pre­ci­sion neu­ro med­i­cine

6 years ago
Financing

Or­biMed-backed Pre­lude Ther­a­peu­tics rais­es $60M to tack­le re­sis­tance to can­cer treat­ments

6 years ago
Financing

Stick­ing to hottest trends in bio­phar­ma, On­colo­gie gath­ers $80M for next leg of trans-Pa­cif­ic clin­i­cal jour­ney

6 years ago

Ar­ti­zan com­pletes mi­cro­bio­me starter pack­age with Brii deal, CSO hire and some mon­ey to dash for the clin­ic

6 years ago
Financing

Third Rock rais­es a record $770M to back its own brand of biotech star­tups — while 1 key part­ner ex­its

6 years ago

A new in­ter­leukin tar­get for NASH spawns Sin­ga­pore­an biotech steered by well known play­ers

6 years ago
Discovery

Ed Kaye is tak­ing his fledg­ling biotech to Wall Street, look­ing for a new in­jec­tion of cash

6 years ago
Financing

Her­cules vet launch­es a new life sci­ences lender with $400M to put in­to play

6 years ago

Some of the best con­nect­ed play­ers in the San Diego hub or­ga­nize launch round for an­oth­er biotech with an eye on tri­al da­ta

6 years ago
R&D

As UK biotech gains steam, Syn­cona launch­es new Treg play­er while Cam­bridge spin­out ex­pands Se­ries A

6 years ago
Financing

$1.3B Keytru­da wind­fall will be used to ac­cel­er­ate trans­la­tion­al drug R&D in the UK

6 years ago
R&D

They got bounced out of Alex­ion. Now David Hal­lal and Vikas Sin­ha are back with $150M and a fo­cus on cell and gene ther­a­pies

6 years ago
Financing

A new­ly formed biotech launched out of George Da­ley’s Har­vard lab adds glob­al play­ers to its syn­di­cate, bring­ing its haul to $83M

7 years ago
R&D

One of the world's top ex­perts in coro­nary heart dis­ease is spear­head­ing a new gene edit­ing up­start out to trans­form the field

7 years ago
People
Cell/Gene Tx

Roche spins out Nim­ble Ther­a­peu­tics to cap­i­tal­ize on pep­tide drug dis­cov­ery, with $10M sup­port from Tele­graph Hill Part­ners

7 years ago

Vow­ing to spark a rev­o­lu­tion in small mol­e­cule R&D, Vi­vid­ion equips it­self with an ex­tra $82M for the fi­nal stretch to the clin­ic

7 years ago
Financing

A biotech fledg­ling cross-bred in France and Switzer­land launch­es to take on liv­er prob­lems of glob­al di­men­sions

7 years ago
Financing

GSK punts a failed car­dio drug to a biotech start­up — which has a new de­vel­op­ment strat­e­gy in mind

7 years ago
R&D
First page Previous page 57585960616263 Next page Last page
A service from the Financial Times